Clinical trials: Advanced Solid Malignant Tumors
Solid Tumors, Neuroendocrine Tumors
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
To select RP2D/MTD of HBM4003 in combination with Toripalimab in dose confirmation part(Part 1) and use the RP2D in dose expansion part (Part 2) to evaluate the safety, tolerability, PK/PD and preliminary efficacy of in patients…
- Conditions
- Solid Tumors, Neuroendocrine Tumors, CRC
- Trial name
- NCT05167071
- Testing
- HBM4003, Toripalimab, Tislelizumab
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.
Advanced Solid Tumor
A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of HS-10386 in participants with advanced solid tumors who have failed prior treatments.
- Trial name
- NCT05911464
- Testing
- HS-10386
- Where
- China
- Volunteers
- 248 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Solid Tumor
A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety of the study drug known as LY3321367, an anti-T-cell immunoglobulin and mucin-domain domain-containing molecule-3 (TIM-3) antibody administered alone or in combination with…
- Trial name
- NCT03099109
- Testing
- LY3321367, LY3300054
- Where
- 15 sites in United States, Japan and 2 more
- Volunteers
- 209 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Advanced Solid Tumors
A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.
- Trial name
- NCT00708006
- Testing
- HGS1029
- Where
- 3 sites in United States
- Volunteers
- 66 people
- Sponsor
- Human Genome Sciences Inc.
Solid Tumor
This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors
This is a multicenter, open-label, phase I dose-escalation and expansion study of IBI3026 in participants with unresectable, locally advanced, or metastatic solid tumors.
- Trial name
- NCT07327632
- Testing
- IBI3026
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative
- Trial name
- DUET-3 (NCT03752398)
- Testing
- XmAb®23104, Yervoy® (ipilimumab)
- Where
- 18 sites in United States
- Volunteers
- 198 people
- Sponsor
- Xencor, Inc.
Advanced Malignant Solid Tumor
Phase I/II Study of SCTB39G in Advanced Solid Tumours
This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB39G as a monotherapy in adult patients with advanced malignant solid tumours.
- Trial name
- NCT07077252
- Testing
- SCTB39G
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sinocelltech Ltd.
Neoplasms
Study Evaluating MST-997 in Advanced Malignant Solid Tumors
The primary objective of this clinical research study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of intravenous (IV) MST-997 formulated in Intralipid 20% administered on a weekly schedule to…
- Trial name
- NCT00088647
- Testing
- MST-997
- Where
- 3 sites in United States
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Cancer, Advanced Solid Tumors
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors.
- Conditions
- Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC), Non-small-cell-lung-cancer (NSCLC)
- Trial name
- NCT03893955
- Testing
- ABBV-927, ABBV-368, ABBV-181
- Where
- 26 sites in United States, Australia and 4 more
- Volunteers
- 150 people
- Sponsor
- AbbVie
Advanced Solid Tumor Cancer
A Study to Evaluate YF087 in Subjects With MSI-H or dMMR Advanced Solid Tumors
This is an open-label, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of YF087 in subjects with Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) advanced solid…
- Trial name
- NCT07809607
- Testing
- YF087
- Volunteers
- 70 people
- Sponsor
- InventisBio Co., Ltd
Locally Advanced or Metastatic Solid Tumors
Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors
This is a phase I study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC3195 in Patients with Locally Advanced or Metastatic Solid Tumors.
- Trial name
- BC3195 (NCT05957471)
- Testing
- Drug: BC3195 for Injection
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Biocity Biopharmaceutics Co., Ltd.
Solid Tumors
An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors
The main aim of this study is to assess how the human body of adults with advanced or metastatic solid tumors absorbs, distributes, metabolizes and excretes subasumstat following a single 1 hour infusion of subasumstat.
- Trial name
- NCT05976334
- Testing
- [14C] Subasumstat, Subasumstat
- Where
- 2 sites in Hungary
- Volunteers
- 3 people
- Sponsor
- Takeda
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Advanced Solid Tumors
A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors
This is a first in human, open-label, sequential dose escalation and expansion study of AMG 780 in up to 62 subjects with advanced solid tumors.
- Trial name
- NCT01137552
- Testing
- AMG 780
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Amgen
Advanced Neoplastic Disease
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors
Primary Objective: To determine the dose limiting toxicity (DLT), the maximum administered dose (MAD) and the maximum tolerated dose (MTD) of AVE8062 and docetaxel in combination administered sequentially on D1 \& D2 respectively…
- Trial name
- NCT01907685
- Testing
- AVE8062, Docetaxel
- Volunteers
- 58 people
- Sponsor
- Sanofi
Cancer, Solid Tumors
Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055
The primary objective is to assess the safety and tolerability of AZD8055 in Japanese patients with advanced solid tumours.
- Conditions
- Cancer, Solid Tumors, Advanced Solid Malignancies
- Trial name
- NCT00973076
- Testing
- AZD8055
- Where
- Japan
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Metastatic and Advanced Solid Tumors
A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers
Phase I/Ib multicenter clinical trial. Single agent dose escalation of NIZ985 followed by expansion. Second escalation of NIZ985 in combination with PDR001 followed by expansion
- Trial name
- NCT02452268
- Testing
- NIZ985, PDR001
- Where
- 7 sites in United States
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms, Pancreatic Neoplasms
Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
The purpose of this study is to determine the safety of glufosfamide when administered in combination with gemcitabine.
- Trial name
- NCT00102752
- Testing
- Glufosfamide, Gemcitabine
- Where
- 9 sites in United States, Brazil
- Volunteers
- 47 people
- Sponsor
- Threshold Pharmaceuticals
Cancer, Solid Tumor Cancer
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies.
- Conditions
- Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate
- Trial name
- NCT07424547
- Testing
- SYS6043
- Where
- 5 sites in United States
- Volunteers
- 386 people
- Sponsor
- Conjupro Biotherapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.